Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
timolol + brimonidine + dorzolamide + bimatoprost
- Development stage
- Phase 4
- Lead developer
- Harrow
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
This quadruple-action topical ophthalmic formulation is used for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is typically prescribed when multi-drug therapy is required and aims to improve patient adherence by consolidating four medications into a single bottle. The combination integrates four distinct mechanisms: timolol (a non-selective beta-blocker) and dorzolamide (a carbonic anhydrase inhibitor) reduce aqueous humor production; brimonidine (an alpha-2 adrenergic agonist) reduces production while increasing uveoscleral outflow; and bimatoprost (a prostaglandin analog/prostamide) enhances both trabecular and uveoscleral drainage. By targeting multiple physiological pathways of aqueous humor dynamics, the formulation provides a potent synergistic effect on IOP reduction compared to monotherapy.
- Brand names
- Quad-ComboOMNI Quad
- Other names
- Tim-Brim-Dor-BimatTimolol/Brimonidine/Dorzolamide/BimatoprostQuadruple Combination Glaucoma Drops
02
Targets
ADRA2 (Adrenergic alpha-2 receptor family)ADRB1 (β1)CA2 (Carbonic Anhydrase 2)PTGFR (Prostaglandin F2 alpha receptor)ADRA2A (α2A)ADRA2B (α2B)ADRA2C (α2C)ADRB2 (β2)
Beyond the preview
Go deeper on timolol + brimonidine + dorzolamide + bimatoprost.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on timolol + brimonidine + dorzolamide + bimatoprost.